Antonio Maria Risitano

Summary

Affiliation: Federico II University
Country: Italy

Publications

  1. doi Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
    Antonio Maria Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy
    Br J Haematol 148:791-6. 2010
  2. doi Immunosuppressive therapies in the management of acquired immune-mediated marrow failures
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Curr Opin Hematol 19:3-13. 2012
  3. pmc Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
    Antonio M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II, University of Naples, Italy
    Biologics 2:205-22. 2008
  4. pmc Aplastic anemia: immunosuppressive therapy in 2010
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Pediatr Rep 3:e7. 2011
  5. doi Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)
    A M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Bone Marrow Transplant 48:186-90. 2013
  6. ncbi Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
    Antonio M Risitano
    Division of Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Via Pansini 5, 80131 Naples Italy
    Adv Exp Med Biol 735:155-72. 2013
  7. doi Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Immunobiology 217:1080-7. 2012
  8. ncbi Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
    Antonio M Risitano
    Division of Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Via Pansini 5, 80131, Naples, Italy
    Adv Exp Med Biol 734:155-72. 2013
  9. doi The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
    Antonio M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Blood 119:6307-16. 2012
  10. ncbi Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes
    Antonio M Risitano
    Division of Hematology, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
    Curr Stem Cell Res Ther 2:39-52. 2007

Collaborators

Detail Information

Publications35

  1. doi Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA
    Antonio Maria Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy
    Br J Haematol 148:791-6. 2010
    ..Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures...
  2. doi Immunosuppressive therapies in the management of acquired immune-mediated marrow failures
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Curr Opin Hematol 19:3-13. 2012
    ..Several attempts have been performed to improve the standard immunosuppression regimen of horse antithymocyte globulin (h-ATG) and cyclosporine A (CyA)...
  3. pmc Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
    Antonio M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II, University of Naples, Italy
    Biologics 2:205-22. 2008
    ..All the data from worldwide clinical trials confirm that eculizumab radically modifies the symptoms, the biology, and the natural history of PNH, strongly improving the quality of life of PNH patients...
  4. pmc Aplastic anemia: immunosuppressive therapy in 2010
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Pediatr Rep 3:e7. 2011
    ..We also discuss very recent data which question the equality of different ATG preparations, leading to a possible reconsideration of the current standards of care for AA patients...
  5. doi Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)
    A M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Naples, Italy
    Bone Marrow Transplant 48:186-90. 2013
    ..Here we describe a consensus regimen that the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party suggests for AA patients failing initial IST who are not indicated for SCT...
  6. ncbi Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
    Antonio M Risitano
    Division of Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Via Pansini 5, 80131 Naples Italy
    Adv Exp Med Biol 735:155-72. 2013
    ....
  7. doi Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Immunobiology 217:1080-7. 2012
    ....
  8. ncbi Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies
    Antonio M Risitano
    Division of Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Via Pansini 5, 80131, Naples, Italy
    Adv Exp Med Biol 734:155-72. 2013
    ....
  9. doi The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment
    Antonio M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Blood 119:6307-16. 2012
    ..TT30 is a membrane-targeted selective CAP inhibitor that may prevent both intravascular and C3-mediated extravascular hemolysis of PNH erythrocytes and warrants consideration for the treatment of PNH patients...
  10. ncbi Function and malfunction of hematopoietic stem cells in primary bone marrow failure syndromes
    Antonio M Risitano
    Division of Hematology, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
    Curr Stem Cell Res Ther 2:39-52. 2007
    ....
  11. doi Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
    Antonio M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Blood 113:4094-100. 2009
    ..Binding of C3 by PNH RBCs may constitute an additional disease mechanism in PNH, strongly enhanced by eculizumab treatment and producing a variable degree of extravascular hemolysis...
  12. ncbi Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients
    A M Risitano
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 19:217-22. 2005
    ....
  13. pmc New challenges to developing animal models for human immune-mediated marrow failure
    Antonio M Risitano
    Division of Hematology, Federico II University of Naples, Via Pansini 5, 80131 Naples, Italy
    Clin Med Res 3:63-4. 2005
  14. ncbi In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing
    Antonio M Risitano
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet 364:355-64. 2004
    ..In most cases, no obvious aetiological factor can be identified. However, clinical responses to immunosuppression strongly suggest an immune pathophysiology...
  15. doi Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going
    Antonio M Risitano
    Department of Biochemistry and Medical Biotechnologies, Federico II University of Naples, Italy
    Br J Haematol 152:127-40. 2011
    ..Specific immunosuppressive strategies employed for other BMFS, such as lineage-restricted marrow failures, myelodysplastic syndromes and large granular lymphocyte leukaemia-associated cytopenias, are also briefly discussed...
  16. ncbi Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3
    A M Risitano
    Hematology, Department of Biochemistry and Medical Biotechnologies, Federico II University, Naples, Italy
    Mini Rev Med Chem 11:528-35. 2011
    ..Finally, we provide a theoretical rationale for the development of novel strategies of complement inhibition which could in the future further improve on the already substantial efficacy of eculizumab...
  17. ncbi Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation
    Patrizia Ricci
    Department of Biochemistry and Medical Biotechnology, Hematology Branch, Federico II University of Naples, Naples, Italy
    Transplantation 82:1449-56. 2006
    ..We investigated OPG and RANKL in serum and marrow plasma in transplanted patients...
  18. ncbi Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation
    Libuse Tauchmanova
    Department of Endocrinology, Division of Rheumatology, Federico II University of Naples, Via S Pansini 5, 80131 Naples, Italy
    J Clin Endocrinol Metab 87:5058-65. 2002
    ..Inability to regenerate a normal number of osteoblastic precursors in the stromal stem cell compartment may in part account for severe long-lasting posttransplant decrease in bone mass...
  19. ncbi Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab
    C Selleri
    Hemato Oncology Department, Medical School, University of Salerno, Italy
    Mini Rev Med Chem 11:536-43. 2011
    ..Even if the dose and the schedule may still require further refining, the available data support the need of large prospective trials comparing alemtuzumab to current standard IS regimens...
  20. ncbi Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia
    Marcin W Wlodarski
    Taussig Cancer Center R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Blood 106:2769-80. 2005
    ..In contrast, the physiologic clonal CTL repertoire is highly diverse and we were not able to detect any significant clonal sharing in 26 healthy controls...
  21. ncbi Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892 1652, USA
    Blood 100:4427-32. 2002
    ..Clinical data demonstrating the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) would favor an active role of the immune system in this syndrome...
  22. ncbi Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry
    Antonio M Risitano
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:178-83. 2002
    ..As V beta skewing may correlate with relative V beta size, oligoclonality in combination with numerical V beta expansion can be applied to recognition of disease-specific T-cell receptors...
  23. ncbi Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia
    Weihua Zeng
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 119:803-9. 2002
    ..These results show that NKT cells are profoundly decreased in AA and MDS, and their deficiency may, as in other human autoimmune diseases, play a role in the local immune dysregulation in AA and MDS...
  24. ncbi Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria
    Jan Simak
    Laboratory of Cellular Hematology, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Br J Haematol 125:804-13. 2004
    ..Analysis of circulating ECMP appears promising to provide useful information on the status of the vascular endothelium in PNH and SCD...
  25. ncbi Shared and individual specificities of immunodominant cytotoxic T-cell clones in paroxysmal nocturnal hemoglobinuria as determined by molecular analysis
    Magdalena Plasilova
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Exp Hematol 32:261-9. 2004
    ..We previously described expansions of selective cytotoxic T-lymphocyte (CTL) clones in AA patients...
  26. ncbi CD34+ cells from paroxysmal nocturnal hemoglobinuria (PNH) patients are deficient in surface expression of cellular prion protein (PrPc)
    Antonio M Risitano
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Exp Hematol 31:65-72. 2003
    ..Conversely, PrP(c) is a good model to elucidate the fate of GPI-AP in PIG-A-deficient cells...
  27. ncbi Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses
    Christine L O'Keefe
    Experimental Hematology and Hematopoiesis Section, and Hematopathology Section, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Immunol 172:1960-9. 2004
    ....
  28. ncbi Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein
    Karel Holada
    Laboratory of Cellular Hematology, Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Blood 100:341-3. 2002
    ..Our results indicate that in the absence of GPI anchor, PrPc can be expressed intracellularly and up-regulated on the platelet membrane, likely in a transmembrane form with the C-terminal part of the molecule inserted into the cytoplasm...
  29. ncbi The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    N Engl J Med 355:1233-43. 2006
    ..We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH)...
  30. ncbi Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients
    Weihua Zeng
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Exp Hematol 32:806-14. 2004
    ..T cells producing IFN-gamma and TNF-alpha have been implicated in hematopoietic destruction in AA. We sought to characterize T cells as immune mediators using the microarray approach...
  31. pmc Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
    Elaine M Sloand
    Hematology Branch, National Heart, Lung, and Blood Institute, Bldg 10, Rm 7C108, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 106:841-51. 2005
    ..An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomy 8 MDS...
  32. doi Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab
    Antonio M Risitano
    Blood 112:449-51. 2008
  33. ncbi Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
    Robert A Brodsky
    Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Blood 111:1840-7. 2008
    ..This trial is registered at http://clinicaltrials.gov as NCT00130000...
  34. ncbi Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
    Peter Hillmen
    Leeds General Infirmary, Leeds, United Kingdom
    Blood 110:4123-8. 2007
    ..001). These results show that eculizumab treatment reduces the risk of clinical thromboembolism in patients with PNH. This study is registered at http://clinicaltrials.gov (study ID no. NCT00122317)...
  35. ncbi Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens
    Hoon Kook
    Hematology Branch of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 99:3668-75. 2002
    ..Our data indicate that multiple specific clones mediate the immune process in AA...